Performance Status News Today

been diagnosed with cancer and is postponing public duties. he left the hospital a week ago after treatment for an enlarged prostate. joining us is nbcs molly hunter. i understand the palace has just released a statement. what are they saying? >> chris, thats right. we just got the statement. im just reading it for the first time as well. the big thing to understand, as you know, we covered the kings health scare last week which was really presented as a routine procedure. he was only ...

Verastem Oncology announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine...

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Expert perspectives on the decision-making process for selecting frontline systemic therapy for patients with advanced renal cell carcinoma.

Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, make introductions and review the current paradigm for small cell lung cancer diagnosis and classification.

Tedopi is the Company's Most Advanced Product in Clinical Development ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi to chemotherapy in non-small cell lung cancer

06.06.2023 - Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented a poster and a publication in abstract book featuring Tedopi, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer (NSCLC) and in ... Seite 1

MRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA aloneThe DMFS results

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.